Authors

Charles J. Ryan, MD, UCSF

Charles J. Ryan, MD, UCSF Helen Diller Comprehensive Cancer Center

Charles J. Ryan, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Charles L. Loprinzi, MD, Mayo Clinic

Charles L. Sawyers, MD

Latest:

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Charles L. Shapiro, MD

Latest:

Dr. Shapiro on Preventative Drugs in Breast Cancer

Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the underutilization of preventative drugs for breast cancer.

Charles Loprinzi, MD, Mayo Clinic Rochester

Charles M. Farber, MD, PhD

Latest:

The Clinical and Economic Value of Rituximab for the Treatment of Hematologic Malignancies

Rituximab is a humanized monoclonal antibody that is used for the treatment of a wide variety of B-cell-derived hematologic malignancies

Charles M. Perou, PhD

Latest:

Charles Perou on Biomarker Assay Use in ASCO Breast Cancer Guideline

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.

Charles M. Rudin, MD

Latest:

Investigational Agents in SCLC in the Second Line Setting and Beyond

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Charles M. Rudin, MD, PhD

Latest:

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.

Charles Powell, MD

Latest:

Optimizing the Management of ILD: Take-Home Messages

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

Charles Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center

Charles Ryan, MD, Masonic Cancer Center

Charles S. Fuchs, MD

Latest:

Dr. Fuchs Discusses Immunotherapy in Gastric Cancer

Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.

Charles S. Fuchs, MD, Dana-Farber Cancer Institute

Charles S. Fuchs, MD, Harvard Medical School

Charles W. Scarantino, MD, PhD

Latest:

Wireless Dosimetry

A new way to ensure your patients receive the proper radiation dose where they need it.

Charlie Gourley, PhD, MBChB

Latest:

Dr. Charlie Gourley on Olaparib Maintenance in Ovarian Cancer

Charlie Lustman

Latest:

Cancer Survivor Charlie Lustman Lives to Tell His Story

Keynote Presenter Cancer Survivor Charlie Lustman Lives to Tell His Story